{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:27:38Z","timestamp":1794590858181,"version":"4.9.1"},"reference-count":18,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The ALPINE trial was a randomized, open-label study comparing the efficacy and safety of zanubrutinib vs ibrutinib monotherapy in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL). Using patient-reported outcome (PRO) data from the ALPINE trial, this study aimed to investigate the associations between disease-specific patient-reported symptoms and the clinical outcomes of progression-free survival (PFS) and duration of response (DoR). After adjusting for baseline stratification factors, zanubrutinib was associated with lower PRO-based recurrent symptomatic deterioration than ibrutinib. Zanubrutinib also demonstrated significantly lower risk of disease progression and better DoR across all disease-specific patient-reported symptoms. Compared with ibrutinib, zanubrutinib demonstrated a 28% to 33% reduction in the risk of a PFS event after adjusting for global health status, physical functioning, role functioning, fatigue, pain, nausea and vomiting, diarrhea, and constipation (all P&amp;lt; .02). Similarly, zanubrutinib demonstrated a 31% to 51% reduced risk of shortened DoR after adjusting for the patient-reported scores (all P&amp;lt; .02). These are crucial aspects in clinical decision-making because they highlight zanubrutinib\u2019s association with improved clinical outcomes and patient-reported symptomatology. These findings reinforce the enhanced efficacy profile of zanubrutinib in patients with R\/R CLL\/SLL by demonstrating its lower patient-reported symptom deterioration in addition to increased PFS and better DoR. This trial was registered at www.clinicaltrials.gov as NCT03734016.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020405","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:16:01Z","timestamp":1789143361000},"page":"7651-7662","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Association between patient-reported symptoms and clinical outcomes in R\/R CLL"],"prefix":"10.1182","volume":"10","author":[{"given":"Timothy","family":"Victor","sequence":"first","affiliation":[{"name":"1Human Development and Quantitative Methods Division, University of Pennsylvania, Philadelphia, PA"},{"name":"2BeOne Medicines Ltd, San Carlos, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisoo","family":"Barnes","sequence":"additional","affiliation":[{"name":"2BeOne Medicines Ltd, San Carlos, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-6562","authenticated-orcid":false,"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[{"name":"3Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"4Hematology and Oncology Division, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3331-9491","authenticated-orcid":false,"given":"Nicole","family":"Lamanna","sequence":"additional","affiliation":[{"name":"5Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-5017","authenticated-orcid":false,"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Alfred Hospital and Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7438-8277","authenticated-orcid":false,"given":"Luigi","family":"Qiu","sequence":"additional","affiliation":[{"name":"7State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommi","family":"Salmi","sequence":"additional","affiliation":[{"name":"8BeOne Medicines Ltd, GmBH, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick B.","family":"Barnes","sequence":"additional","affiliation":[{"name":"2BeOne Medicines Ltd, San Carlos, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasika","family":"Korde","sequence":"additional","affiliation":[{"name":"2BeOne Medicines Ltd, San Carlos, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-4961","authenticated-orcid":false,"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[{"name":"9Chronic Lymphocytic Leukemia Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2026111311220271700_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"issue":"9","key":"2026111311220271700_bib2","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1080\/03007995.2020.1784120","article-title":"Health-related quality of life and economic burden of chronic lymphocytic leukemia in the era of novel targeted agents","volume":"36","author":"Waweru","year":"2020","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"2026111311220271700_bib3","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1007\/s11136-015-1039-y","article-title":"Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study","volume":"24","author":"Holtzer-Goor","year":"2015","journal-title":"Qual Life Res"},{"issue":"2","key":"2026111311220271700_bib4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2141.2007.06791.x","article-title":"Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients","volume":"139","author":"Shanafelt","year":"2007","journal-title":"Br J Haematol"},{"issue":"4","key":"2026111311220271700_bib5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"26","key":"2026111311220271700_bib6","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1182\/blood.2024024667","article-title":"Sustained benefit of zanubrutinib vs ibrutinib in patients with R\/R CLL\/SLL: final comparative analysis of ALPINE","volume":"144","author":"Brown","year":"2024","journal-title":"Blood"},{"issue":"11","key":"2026111311220271700_bib7","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1080\/03007995.2023.2262378","article-title":"Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from the ALPINE Trial","volume":"39","author":"Tam","year":"2023","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"2026111311220271700_bib8","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1016\/j.cllc.2020.09.014","article-title":"Patient-reported outcome measures used in routine care predict for survival at disease progression in patients with advanced lung cancer","volume":"22","author":"Friis","year":"2021","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"2026111311220271700_bib9","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jval.2020.10.017","article-title":"Patient-reported outcomes as independent prognostic factors for survival in oncology: systematic review and meta-analysis","volume":"24","author":"Efficace","year":"2021","journal-title":"Value Health"},{"issue":"2","key":"2026111311220271700_bib10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/cncr.20010","article-title":"Quality of life as a survival predictor for patients with advanced head and neck carcinoma treated with radiotherapy","volume":"100","author":"Fang","year":"2004","journal-title":"Cancer"},{"issue":"1","key":"2026111311220271700_bib11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1200\/JCO.1996.14.1.171","article-title":"Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases","volume":"14","author":"Earlam","year":"1996","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026111311220271700_bib12","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1200\/JCO.2007.13.3439","article-title":"The prognostic significance of patient-reported outcomes in cancer clinical trials","volume":"26","author":"Gotay","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026111311220271700_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s41687-024-00708-w","article-title":"Are changes in patient-reported outcomes prognostic for diffuse large B-cell lymphoma survival? Results from the GOYA trial","volume":"8","author":"Yan","year":"2024","journal-title":"J Patient Rep Outcomes"},{"issue":"2","key":"2026111311220271700_bib14","first-page":"231","article-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) adopts consolidated guideline on good clinical practice in the conduct of clinical trials on medicinal products for human use","volume":"48","year":"1997","journal-title":"Int Dig Health Legis"},{"issue":"5","key":"2026111311220271700_bib15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"2026111311220271700_bib16","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"1","key":"2026111311220271700_bib17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"issue":"11","key":"2026111311220271700_bib18","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1177\/0962280220921889","article-title":"A tutorial on frailty models","volume":"29","author":"Balan","year":"2020","journal-title":"Stat Methods Med Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/22\/7651\/2600095\/blooda_adv-2026-020405-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/22\/7651\/2600095\/blooda_adv-2026-020405-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:22:10Z","timestamp":1794586930000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/22\/7651\/570925\/Association-between-patient-reported-symptoms-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11,24]]},"references-count":18,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2026,11,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020405","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11,24]]},"published":{"date-parts":[[2026,11,24]]}}}